83,020 Shares in Amicus Therapeutics, Inc. (NASDAQ:FOLD) Bought by Teachers Retirement System of The State of Kentucky

Teachers Retirement System of The State of Kentucky purchased a new stake in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 83,020 shares of the biopharmaceutical company’s stock, valued at approximately $1,178,000.

Several other institutional investors have also bought and sold shares of FOLD. Norges Bank purchased a new stake in shares of Amicus Therapeutics during the 4th quarter valued at about $35,915,000. UBS Group AG increased its stake in Amicus Therapeutics by 58.1% during the fourth quarter. UBS Group AG now owns 824,708 shares of the biopharmaceutical company’s stock worth $11,703,000 after acquiring an additional 303,038 shares during the last quarter. Massachusetts Financial Services Co. MA raised its position in Amicus Therapeutics by 32.6% during the fourth quarter. Massachusetts Financial Services Co. MA now owns 2,415,090 shares of the biopharmaceutical company’s stock valued at $34,270,000 after purchasing an additional 593,131 shares during the period. Blackstone Inc. bought a new stake in shares of Amicus Therapeutics in the 4th quarter valued at approximately $35,008,000. Finally, Vontobel Holding Ltd. purchased a new position in shares of Amicus Therapeutics in the 4th quarter worth approximately $1,173,000.

Amicus Therapeutics Stock Performance

Shares of NASDAQ:FOLD opened at $10.09 on Monday. The firm’s 50 day simple moving average is $10.05 and its 200-day simple moving average is $11.76. The company has a debt-to-equity ratio of 2.97, a quick ratio of 2.61 and a current ratio of 3.03. Amicus Therapeutics, Inc. has a one year low of $9.02 and a one year high of $14.57. The firm has a market cap of $2.99 billion, a PE ratio of -20.59 and a beta of 0.74.

Amicus Therapeutics (NASDAQ:FOLD) last announced its quarterly earnings data on Thursday, May 9th. The biopharmaceutical company reported ($0.02) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.06) by $0.04. Amicus Therapeutics had a negative return on equity of 77.08% and a negative net margin of 34.73%. The company had revenue of $110.40 million for the quarter, compared to analysts’ expectations of $111.19 million. During the same quarter in the prior year, the firm earned ($0.18) earnings per share. Amicus Therapeutics’s revenue was up 27.9% compared to the same quarter last year. As a group, equities analysts predict that Amicus Therapeutics, Inc. will post -0.12 EPS for the current year.

Analysts Set New Price Targets

Several research firms recently weighed in on FOLD. Bank of America decreased their price target on Amicus Therapeutics from $14.00 to $13.00 and set a “buy” rating on the stock in a report on Friday, May 10th. JPMorgan Chase & Co. reduced their target price on shares of Amicus Therapeutics from $21.00 to $19.00 and set an “overweight” rating on the stock in a research note on Monday, March 18th. UBS Group dropped their price target on shares of Amicus Therapeutics from $20.00 to $19.00 and set a “buy” rating for the company in a research note on Friday, May 10th. Wells Fargo & Company assumed coverage on shares of Amicus Therapeutics in a research report on Thursday, May 30th. They issued an “overweight” rating and a $18.00 price objective on the stock. Finally, Needham & Company LLC reissued a “hold” rating on shares of Amicus Therapeutics in a research note on Friday, May 10th. Two equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Amicus Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $17.57.

Insider Buying and Selling

In other Amicus Therapeutics news, CEO Bradley L. Campbell sold 7,500 shares of the firm’s stock in a transaction dated Wednesday, May 1st. The shares were sold at an average price of $10.07, for a total transaction of $75,525.00. Following the transaction, the chief executive officer now owns 886,654 shares of the company’s stock, valued at approximately $8,928,605.78. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 2.20% of the stock is owned by insiders.

Amicus Therapeutics Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.